8月13日,康希诺生物股份公司正在上海证券交易所科创板成功上市,此次上市募集资金总额超过52亿元。天元律师事务所担任发行人律师。

康希诺生物于2009年成立于天津,是一家研发、生产和销售符合中国及国际标准的创新型疫苗企业。2019年3月,康希诺生物在香港交易所上市。此次科创板上市后,康希诺生物成为首个“A+H”疫苗股,同时还是继君实生物今年7月登陆科创板后的第二家“H股+科创板” 未盈利生物科技股。

天元团队的牵头律师为合伙人刘艳、傅思齐、甄月能。

本次IPO的承销商是中信证券、中金公司和渤海证券。

Tian Yuan acts on CanSino Biologics’STAR Market IPO

Tian Yuan Law Firm has advised biotech company CanSino Biologics on its $749 million initial public offering on the Shanghai STAR Market.

Established in 2009, the Tianjin-headquartered CanSino focuses on the research, development, production and selling of innovative vaccines. In March 2019, CanSino launched its IPO in Hong Kong Stock Exchange. With this STAR Market IPO, CanSino has become the first vaccine company to have a dual listing to be listed in both Hong Kong and Shanghai, and also the second pre-revenue biotech company to list in both places after Junshi Biosciences’ STAR Market IPO in this July.

The Tian Yuan team was led by partners Liu Yan, Fu Siqi and Zhen Yueneng. The underwriters of this IPO are CITIC Securities, CICC and Bohai Securities.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.